# Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

- URL: https://theranews.net/blog/2026-04-23-vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-applicat-f553a9/
- Published: 2026-04-23
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: rutlandherald
- Original report: https://www.rutlandherald.com/news/business/vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-application-enabling-further-phase/article_17520fd3-203b-5e31-8c49-0731ba5de28d.html
- Topics: anxiety
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 22, 2026--

---
![Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause](/uploads/news-images/vistagen-receives-fda-study-may-proceed-letter-u-20260423110035.jpg)

---
*Originally reported by rutlandherald. [Read more](https://www.rutlandherald.com/news/business/vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-application-enabling-further-phase/article_17520fd3-203b-5e31-8c49-0731ba5de28d.html)*

---

*Source: [https://www.rutlandherald.com/news/business/vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-application-enabling-further-phase/article_17520fd3-203b-5e31-8c49-0731ba5de28d.html](https://www.rutlandherald.com/news/business/vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-application-enabling-further-phase/article_17520fd3-203b-5e31-8c49-0731ba5de28d.html)*